A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

Summary

The study will assess the efficacy and safety of 2 dose regimens of pegozafermin compared to placebo for the treatment of liver fibrosis stage F2 or F3 in adult participants with MASH.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 80 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

89bio, Inc.

Last updated on ClinicalTrials.gov

October 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites